 not reached ezetimibe can
be added, which is available in combination tablets with
both statins. These treatments have limited side effects
in most (but not all) people and are relatively inexpensive. According to the recent ESC-EASD and ESC-EAS
guidelines, an LDL level below 1.0 mmol/L (40 mg/dL)
can be the target in people with recurrent cardiovascular
events (within two years), based on a limited number of
